CTL@WCM Office Hours with Jamie Brisbois
2026-04-29 14:00 - 16:00 UTC | NY
CTL@WCM Office Hours are open to all who wish to gain more information about the advancement of their patent filings and to discuss their technology venture project with a one-on-one meeting with a Weill Cornell Business Development and Licensing Officer.
The April 29th office hours will be hosted virtually by Jamie Brisbois, Business Development and Licensing Associate at CTL, NYC office, from 2 – 4 p.m.
Jamie assists the licensing team in identifying, marketing, and licensing life sciences technologies developed at Weill Cornell Medicine.
Before joining CTL in 2021, Jamie worked as a consultant with ClearView Healthcare Partners, a boutique healthcare consulting firm based in Boston. In addition, he served three years as a fellow with Columbia Technology Ventures (CTV), the technology transfer office of Columbia University.
Jamie received his Ph.D. in Chemistry from Columbia University, where he helped develop a scalable signaling language for engineering multicellular communication in the laboratory of Dr. Virginia Cornish. Jamie holds a B.A. in Chemistry, Biochemistry, and French from Lawrence University (Appleton, WI), where he graduated Magna Cum Laude.
Register here.

Lab to Impact: The Hard Reality of Building a Biotech Startup - A CEO's Perspective
2026-05-06 12:00 - 13:00 (America/New_York) | https://ctl.cornell.edu/event/lab-to-impact-the-hard-reality-of-building-a-biotech-startup-a-ceos-perspective
What does it take to build a biotechnology company that advances early academic assets into a therapy used at the bedside, while overcoming the scientific, clinical, and financial hurdles along the way?
In this session, Laurence Blumberg, MD, MBA, a physician and serial biotech entrepreneur, shares a candid perspective drawn from decades of experience founding biotechnology companies and advancing scientific discoveries into clinical development. As founding CEO of Syntimmune, he guided the company through early clinical development before its acquisition by Alexion in 2018 for up to $1.2 billion. Earlier, he co-founded Syntonix Pharmaceuticals, where his early strategic vision helped shape a protein engineering platform later acquired by Biogen in 2007. That platform ultimately enabled the development of Eloctate and Alprolix, long-acting therapies for hemophilia A and B that have significantly improved care for patients with bleeding disorders.
This conversation examines the operational and strategic realities of building a therapeutics company. Topics will include:

Understanding the structure of the biotechnology ecosystem
Developing a rigorous Target Product Profile and market thesis
Deciding when to build internal capabilities versus leveraging external partners such as CROs and CDMOs
Securing the capital and strategic partnerships required to advance therapies through development

Researchers, physicians, and aspiring bioentrepreneurs are invited to join this candid conversation.
Hosted by Lynda Inseque, director of Technology & Venture Initiatives and Engagement at CTL.
Register here.

Bearers of Innovation 2026
2026-05-20 11:30 - 13:45 (America/New_York) | NY
Bearers of Innovation: A One Cornell Celebration is an annual, invitation-only celebration recognizing Cornell researchers and inventors who took a meaningful step forward in the technology commercialization journey — whether by disclosing a technology for the first time or reaching a licensing milestone.
This year’s celebration honors inventors from FY2024 and FY2025 across Cornell’s Ithaca and New York City campuses, bringing together the broader Cornell innovation community to recognize the work that moves discoveries from the lab toward real-world impact.
Attendance is by invitation only. Invitations are extended directly to recognized inventors by CTL leadership and the Business Development and Licensing team.

Venturium Spring '26 - Academic Venture Showcase
2026-06-11 11:30 - 13:30 (America/New_York)
Venturium’26 is a virtual, half-day showcase for spinouts from several academic institutions across the USA. The selected companies are actively raising a pre-seed or seed round to drive development and commercialization.
​Why Attend? This one-of-a-kind event allows our audience of venture capital firms, venture studios, accelerators, incubators, and industry professionals to explore a curated selection of companies and innovative technologies.
Cornell startup MAV Unlimited has been selected to pitch at this event.
​Attend to meet academic spinouts representing a variety of esteemed academic institutions, including: California State University – Long Beach, Cornell University, Northeastern University, Rutgers University, University of Kentucky, University of Pennsylvania, Vanderbilt, and Washington University – St. Louis.
​A full agenda for Venturium Spring’26, including company names and contact information, will be published the week of the event. Venturium will encompass pitches from companies commercializing across life, physical, and software sciences.
​Timing of event:

​11:30-11:45 | Welcome from the Academic Institutions Powering Venturium Spring’26

​11:45-1:05 | Presentations featuring Early-stage Ventures

​1:05-1:25 | Networking in Breakout Rooms

​1:25-1:30 | Closing Remarks

​Join us to discover new ventures, form strategic partnerships, and contribute to the growth of these companies. This event is a valuable platform for networking, learning, and fostering meaningful collaborations.
Register for the event.

PORTENT 2026 Annual Meeting
2026-07-09 08:00 - 2026-07-10 17:00 (America/New_York) | NY
PORTENT is Cornell’s NIH-supported Center for Point-of-Care Technologies for Nutrition, Infection, and Cancer. Its mission is to advance point-of-care medical technologies through innovation awards, clinical validation support, Lab-to-Market programming, and commercialization-oriented mentorship.
The showcase will feature current PORTENT performer teams and a select group of additional point-of-care technology companies from the New York City/Cornell ecosystem.

Register here.
